Abstract | BACKGROUND: Metastasized soft-tissue sarcomas still pose a significant therapeutic challenge given the limited efficacy of currently available multimodal treatment strategies. Recent progress in molecular characterization of sarcoma subtypes has enabled successful personalized therapy approaches in a minority of selected patients with targetable mutations. However, in the majority of patients with refractory soft tissue sarcomas, long-term survival remains poor. METHODS: RESULTS: In response to salvage chemotherapy with Docetaxel and Gemcitabine, one patient exhibited a partial remission, and two patients showed stable disease. Patient 1 exhibited stable disease for 6 months during Gemcitabine maintenance therapy before suffering rapid progression of hepatic metastases. Patient 2 underwent 21 months of Gemcitabine maintenance therapy, which was discontinued after progressive pulmonary metastases were detected. Patient 3 is still being treated with Gemcitabine maintenance therapy. Remarkably, owing to significant chemotherapy-associated hematotoxicity, the dose of Gemcitabine dose was reduced by two-thirds. Nevertheless, stable disease with constant pulmonary metastases has been maintained in this patient for 14 months. CONCLUSIONS:
|
Authors | Dennis Christoph Harrer, Sebastian Buschauer, Ulrich Sterz, Karin Menhart, Christina Wendl, Daniel Heudobler, Matthias Grube, Tobias Pukrop, Wolfgang Herr, Martin Vogelhuber |
Journal | Frontiers in oncology
(Front Oncol)
Vol. 11
Pg. 755439
( 2021)
ISSN: 2234-943X [Print] Switzerland |
PMID | 34970483
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Harrer, Buschauer, Sterz, Menhart, Wendl, Heudobler, Grube, Pukrop, Herr and Vogelhuber. |